影响埃特罗利祖马布免疫性和临床后果的因素
Gizette Sperinde1, Yenny Webb-Vargas2, Zicheng Hu3
1BioAnalytical Sciences, Genentech, Inc. 1 DNA Way, South San Francisco, CA, United States of America. sperinde.gizette@gene.com.
这项研究调查了性结肠炎 (UC) 和克罗恩病 (CD) 中对乙利祖马布的免疫反应,该研究发现了与抗药抗体 (ADA) 相关的特定HLA等位基因. 然而,ADA对治疗结果的影响很小.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 炎症性肠病 (IBD),包括性结肠炎 (UC) 和克罗恩病 (CD),需要有效的治疗方法.
- 抗整合素单克隆抗体埃特罗利祖马布最初表现有希望,但在III期试验中失败.
- 了解患者对生物制剂 (如乙利祖马布) 的免疫反应对于未来的药物开发至关重要.
研究的目的:
- 在IBD患者中研究乙利祖马布的免疫性.
- 识别与抗药抗体 (ADA) 发展相关的因素,包括人类白细胞抗原 (HLA) 基因.
- 评估ADA对乙利祖马布安全性和疗效的临床影响.
主要方法:
- 对抗药物抗体 (ADA) 和中和抗体 (NAb) 发展的分析.
- 逻辑回归用于评估ADA/NAb和HLA等位基因之间的关联,年龄,性别和免疫抑制药物使用.
- 评估ADA对药理动力学 (PK),安全性和疗效终点的影响.
主要成果:
- 两个II类HLA基因,HLA-DQB1*06:03和HLA-DQA1*03:03,与ADA和NAb发育的增加有关.
- 没有观察到ADA对乙利祖马布的药理学,安全性或疗效的显著影响.
- 还检查了患者的基线特征和IS药物的使用,以确定它们在免疫性方面的作用.
结论:
- 特定的HLA基因基因与IBD患者的埃特罗利祖马布免疫性有关.
- 尽管开发了ADA,但对安全性和疗效的临床影响很小.
- 结果为未来的生物发育和IBD试验中的患者选择提供了洞察力.
更多相关视频
07:52Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
相关概念视频
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Factors Affecting Drug Response: Overview
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
